Katarzyna Muszynska-Roslan
Overview
Explore the profile of Katarzyna Muszynska-Roslan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pawinska-Wasikowska K, Czogala M, Bukowska-Strakova K, Surman M, Rygielska M, Ksiazek T, et al.
Front Pediatr
. 2024 Nov;
12:1482720.
PMID: 39483533
Background: A personalised approach to the treatment of acute myeloid leukemia (AML) in children and adolescents, as well as the development of supportive therapies, has significantly improved survival. Despite this,...
2.
Kozlowski K, Kononczuk K, Muszynska-Roslan K, Zelazowska-Rutkowska B, Taranta-Janusz K, Werbel K, et al.
J Clin Med
. 2024 May;
13(10).
PMID: 38792509
The survival rate among pediatric cancer patients has reached 80%; however, these childhood cancer survivors (CCSs) are at a heightened risk of developing chronic conditions in adulthood, particularly kidney and...
3.
Pawinska-Wasikowska K, Czogala M, Bukowska-Strakova K, Surman M, Rygielska M, Ksiazek T, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539480
Background: The reports of studies that compare the survival of adolescents and young adults with younger children with acute myeloid leukemia (AML) are contradictory. Patients And Methods: We retrospectively analyzed...
4.
Samborska M, Skalska-Sadowska J, Achkar R, Wachowiak J, Derwich K, Czogala M, et al.
Contemp Oncol (Pozn)
. 2024 Feb;
27(4):249-254.
PMID: 38405205
Introduction: This study aimed to present the clinical features and results of treatment of patients diagnosed with refractory or relapsed acute myeloid leukaemia (AML) in Polish Paediatric Leukaemia/Lymphoma Study Group...
5.
Czogala M, Muszynska-Roslan K
Front Pediatr
. 2023 Dec;
11:1335940.
PMID: 38116579
No abstract available.
6.
Czogala M, Czogala W, Pawinska-Wasikowska K, Ksiazek T, Bukowska-Strakova K, Sikorska-Fic B, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760526
Background: The FMS-like tyrosine kinase 3 (FLT3) gene mutated in 10-15% of pediatric acute myeloid leukemia (AML) is associated with an inferior outcome. The aim of the study was to...
7.
Latoch E, Kozlowski K, Kononczuk K, Zelazowska-Rutkowska B, Tomczuk-Ostapczuk M, Krawczuk-Rybak M, et al.
Nutrients
. 2023 May;
15(10).
PMID: 37242216
Childhood cancer survivors (CCS) are predisposed to developing numerous late effects of anticancer treatment later in life. The existing literature suggests that vitamin D deficiency (VDD) may influence cardiovascular abnormalities...
8.
Czogala M, Czogala W, Pawinska-Wasikowska K, Ksiazek T, Bukowska-Strakova K, Sikorska-Fic B, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765692
Acute P./myeloid leukemia post cytotoxic therapy (AML-pCT) is rare complication of cancer treatment in childhood. The objective of the study was to identify clinical characteristics and provide an analysis of...
9.
Sztolsztener K, Zywno H, Hodun K, Kononczuk K, Muszynska-Roslan K, Latoch E
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142534
Patients suffering from childhood acute lymphoblastic leukemia (ALL) are at risk of late adverse treatment-related effects. The examination of targeted biomarkers could be used to improve the diagnosis and prediction...
10.
Latoch E, Kononczuk K, Konstantynowicz-Nowicka K, Muszynska-Roslan K, Sztolsztener K, Chabowski A, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626130
Childhood acute lymphoblastic leukemia (ALL) survivors are at higher risk of developing many late effects later in life. They experience multiple health problems that have significant public health implications, such...